Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Nov 27;2(22):3193-3195.
doi: 10.1182/bloodadvances.2018027078.

Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients

Stefan Willmann  1 , Liping Zhang  2 , Hannah Mayer  3 , Hans-Ulrich Siegmund  3 , Takahiko Tanigawa  4 , Masato Kaneko  4 , Gary Peters  5 , Jeffrey I Weitz  6   7 , Scott D Berkowitz  8 , Rolf Burghaus  1
Affiliations
Comment

Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients

Stefan Willmann et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.W., R.B., H.M., and H.-U.S. are employees of Bayer AG. R.B., H.M., and H.-U.S. own stock in Bayer AG. L.Z. and G.P. are employees of Janssen Research & Development LLC and own stock in Johnson & Johnson. J.I.W. is a consultant for and has received honoraria from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Ionis, Janssen, Merck, Novartis, Pfizer, and Portola. S.D.B. is an employee of Bayer US LLC. T.T. and M.K. are employees of Bayer Yakuhin Ltd.

Figures

Figure 1.
Figure 1.
Associations between model-estimated PT ratio, mean CHADS2score, and risk of major bleeding events. Population means of the time average of the PT ratio were digitized from Figure 2B and mean CHADS2 scores and probability of event were taken from Table 1 in Yoshioka et al.
See this image and copyright information in PMC

Comment on

References

    1. Yoshioka H, Sato H, Hatakeyama H, Hisaka A. Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. Blood Adv. 2018;2(10):1066-1075. - PMC - PubMed
    1. Kim PY, Yeh CH, Dale BJ, et al. . Mechanistic basis for the differential effects of rivaroxaban and apixaban on global tests of coagulation. TH Open. 2018;02(02):e190-e201. - PMC - PubMed
    1. Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol. 2016;38(5):505-513. - PubMed
    1. Dale BJ, Ginsberg JS, Johnston M, Hirsh J, Weitz JI, Eikelboom JW. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. J Thromb Haemost. 2014;12(11):1810-1815. - PubMed
    1. Bristol-Myers Squibb-Pfizer. Eliquis 2.5 mg film-coated tablets (apixaban). https://www.medicines.org.uk/emc/product/4756/smpc. Accessed 4 October 2018.